Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Notes Payables (2016 - 2023)

Fortress Biotech has reported Notes Payables over the past 10 years, most recently at $3.0 million for Q1 2023.

  • Quarterly results put Notes Payables at $3.0 million for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was $3.0 million (changed N/A YoY), and the annual figure for FY2022 was $2.9 million, up 263.05%.
  • Notes Payables for Q1 2023 was $3.0 million at Fortress Biotech, up from $2.9 million in the prior quarter.
  • Over the last five years, Notes Payables for FBIO hit a ceiling of $84.0 million in Q3 2019 and a floor of $812000.0 in Q4 2021.
  • Median Notes Payables over the past 5 years was $12.5 million (2020), compared with a mean of $30.7 million.
  • Biggest five-year swings in Notes Payables: soared 827.92% in 2019 and later plummeted 82.48% in 2020.
  • Fortress Biotech's Notes Payables stood at $7.2 million in 2019, then surged by 611.81% to $51.4 million in 2020, then plummeted by 98.42% to $812000.0 in 2021, then surged by 263.05% to $2.9 million in 2022, then rose by 1.76% to $3.0 million in 2023.
  • The last three reported values for Notes Payables were $3.0 million (Q1 2023), $2.9 million (Q4 2022), and $812000.0 (Q4 2021) per Business Quant data.